Immunogenetic Modulators of Mucosal Protection From HIV-1 (Kinga)

Clinical Trial ID NCT03701802

PubWeight™ 0.00^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT03701802

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.	N Engl J Med	2012	27.84
2	Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis.	J Infect Dis	2001	6.35
3	Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples.	J Infect Dis	2012	3.06
4	CD4+ T cell responses in HIV-exposed seronegative women are qualitatively distinct from those in HIV-infected women.	J Infect Dis	2004	1.09
5	Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: the PROMISE Study.	J Am Coll Cardiol	1993	1.02
6	TLR activation pathways in HIV-1-exposed seronegative individuals.	J Immunol	2010	1.00
7	Quantifying ongoing HIV-1 exposure in HIV-1-serodiscordant couples to identify individuals with potential host resistance to HIV-1.	J Infect Dis	2012	0.94
8	Differential regulatory T cell activity in HIV type 1-exposed seronegative individuals.	AIDS Res Hum Retroviruses	2013	0.84
9	Antiretroviral Pre-Exposure Prophylaxis Does Not Enhance Immune Responses to HIV in Exposed but Uninfected Persons.	J Infect Dis	2014	0.83
10	Regulatory T-Cell Activity But Not Conventional HIV-Specific T-Cell Responses Are Associated With Protection From HIV-1 Infection.	J Acquir Immune Defic Syndr	2016	0.75
11	HIV-1-Neutralizing IgA Detected in Genital Secretions of Highly HIV-1-Exposed Seronegative Women on Oral Preexposure Prophylaxis.	J Virol	2016	0.75